Using 4-drug combination therapy adds up for man with PAH: Case
A 68-year-old man with severe PAH and multiple coexisting conditions experienced marked improvement after receiving combination therapy.| Pulmonary Hypertension News
A 68-year-old man with severe PAH and multiple coexisting conditions experienced marked improvement after receiving combination therapy.| Pulmonary Hypertension News
Steve Bryson is a science writer for Pulmonary Hypertension News with a PhD in biochemistry. He covers the latest news and information on a variety of pulmonary hypertension topics.| Pulmonary Hypertension News
Three months of CS1 therapy boosted quality of life, while symptoms tied to heart failure and clinical worsening and mortality risk declined.| Pulmonary Hypertension News
Cereno's expanded access program for investigational therapy CS1 covers 10 PAH patients, following a Phase 2a clinical trial.| Pulmonary Hypertension News
The investigational therapy CS1 led to beneficial changes in for people with pulmonary arterial hypertension in a Phase 2a clinical trial.| Pulmonary Hypertension News
The FDA has approved the use of Cereno Scientific’s CS1 in an extension of the ongoing Phase 2 trial testing the therapy in people with PAH.| Pulmonary Hypertension News
After positive trial results for TX45, Tectonic Therapeutic is planning a Phase 2 study to test its effects on blood flow in PH-ILD patients.| Pulmonary Hypertension News
A 5-year-old boy with a neuroblastoma developed PAH after receiving a high dose of chemotherapy to prepare for a stem cell transplant.| Pulmonary Hypertension News
Marisa Wexler is a senior science writer for Pulmonary Hypertension News with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of pulmonary hypertension topics.| Pulmonary Hypertension News
Corvista Health’s point-of-care device, used to predict pulmonary hypertension (PH), also appears to work well at identifying heart failure.| Pulmonary Hypertension News
The FDA granted breakthrough device designation to CorVista for its system diagnosing pulmonary hypertension and cardiovascular disorders.| Pulmonary Hypertension News
Margarida Maia is a science writer for Pulmonary Hypertension News with a PhD in biomedical sciences. She covers the latest news and information on a variety of pulmonary hypertension topics.| Pulmonary Hypertension News
The Aeson Total Artificial Heart helped three people with heart failure and pulmonary hypertension become eligible for a heart transplant.| Pulmonary Hypertension News
Researchers developed a tool for predicting the prognosis of people with chronic lung disease-related pulmonary hypertension.| Pulmonary Hypertension News
A larger diameter of the main pulmonary artery predicts poorer outcomes in pulmonary arterial hypertension (PAH) patients, a study found.| Pulmonary Hypertension News
The FDA has approved Yutrepia, an inhaled treprostinil formulation, for the treatment of PAH and PH-ILD, two forms of pulmonary hypertension.| Pulmonary Hypertension News
Corsair Pharma is planning a Phase 1 clinical trial of its treprostinil skin patch as a treatment for pulmonary arterial hypertension (PAH).| Pulmonary Hypertension News
In hypoxic pulmonary hypertension, exosomes derived from stem cells may be a therapy option for preventing abnormal muscle cell growth.| Pulmonary Hypertension News
Early treatment with iNO and pulmonary surfactant reduces the risk of developing BPD associated with PH in preterm infants, a study found.| Pulmonary Hypertension News
Sensydia has completed a development study of its Cardiac Performance System device to detect pulmonary hypertension and heart failure.| Pulmonary Hypertension News
Sensydia reports completing a 5th study supporting algorithms for its Cardiac Performance System to quickly detect pulmonary hypertension.| Pulmonary Hypertension News
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto...| Pulmonary Hypertension News
Increasing irisin, found at lower levels in people with PAH, may help slow disease progression by stopping vascular remodeling, per a study.| Pulmonary Hypertension News
A protein called BMPER found at low levels in models has emerged as a PAH treatment target as it may ease disease progression, per a study.| Pulmonary Hypertension News
A trial of Insmed’s TPIP suggests daily doses of the inhaled dry powder are well tolerated and may improve blood flow in adults with PAH.| Pulmonary Hypertension News
Adding more lines of treatment may reduce the risk of rehospitalization among adults with PAH who are taking only one medication, per a study.| Pulmonary Hypertension News
Low-dose metformin delivered to the pulmonary arteries using lipid-based nanocapsules, safely eased signs of PAH in rats.| Pulmonary Hypertension News
Many patients with heart dysfunction have pulmonary hypertension, more so if they have enlarged hearts or irregular heartbeats, per a study.| Pulmonary Hypertension News
Using a machine-learned algorithm, Corvista's system can accurately diagnose pulmonary hypertension in a noninvasive way, a study shows.| Pulmonary Hypertension News
Category archive page for News.| Pulmonary Hypertension News
Lindsey Shapiro is a science writer for Pulmonary Hypertension News with a PhD in neuroscience. She covers the latest news and information on a variety of pulmonary hypertension topics.| Pulmonary Hypertension News
A combination treatment may improve survival in patients with both pulmonary hypertension and pulmonary fibrosis, a study found.| Pulmonary Hypertension News
A pivotal study testing Sensydia's noninvasive device, which may help diagnose pulmonary hypertension, enrolled its first participant.| Pulmonary Hypertension News
Cereno Scientific reported a successful meeting with the FDA on the design of a future clinical trial for its PAH therapy candidate CS1.| Pulmonary Hypertension News
Heart failure related to PAH is becoming more common, with patients living fewer years in full health, a trend that’s predicted to continue.| Pulmonary Hypertension News
